These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

134 related articles for article (PubMed ID: 15168671)

  • 1. Ethical aspects of genetic screening in Israel.
    Sagi M
    Sci Context; 1998; 11(3-4):419-29. PubMed ID: 15168671
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Carrier screening for cystic fibrosis, Gaucher disease, and Tay-Sachs disease in the Ashkenazi Jewish population: the first 1000 cases at New York University Medical Center, New York, NY.
    Kronn D; Jansen V; Ostrer H
    Arch Intern Med; 1998 Apr; 158(7):777-81. PubMed ID: 9554684
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Population-specific screening by mutation analysis for diseases frequent in Ashkenazi Jews.
    DeMarchi JM; Caskey CT; Richards CS
    Hum Mutat; 1996; 8(2):116-25. PubMed ID: 8844209
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Ethical Issues with Genetic Testing for Tay-Sachs.
    Clayton T
    J Christ Nurs; 2017; 34(4):246-249. PubMed ID: 28902054
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Screening for genetic disorders among Jews: how should the Tay-Sachs screening program be continued?
    Zlotogora J; Leventhal A
    Isr Med Assoc J; 2000 Sep; 2(9):665-7. PubMed ID: 11062764
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Screening for carriers of Tay-Sachs disease in the ultraorthodox Ashkenazi Jewish community in Israel.
    Broide E; Zeigler M; Eckstein J; Bach G
    Am J Med Genet; 1993 Aug; 47(2):213-5. PubMed ID: 8213907
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Prenatal genetic carrier testing using triple disease screening.
    Eng CM; Schechter C; Robinowitz J; Fulop G; Burgert T; Levy B; Zinberg R; Desnick RJ
    JAMA; 1997 Oct; 278(15):1268-72. PubMed ID: 9333269
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A genetic screening programme for Tay-Sachs disease and cystic fibrosis for Australian Jewish high school students.
    Barlow-Stewart K; Burnett L; Proos A; Howell V; Huq F; Lazarus R; Aizenberg H
    J Med Genet; 2003 Apr; 40(4):e45. PubMed ID: 12676918
    [No Abstract]   [Full Text] [Related]  

  • 9. Ashkenazi Jews and breast cancer: the consequences of linking ethnic identity to genetic disease.
    Brandt-Rauf SI; Raveis VH; Drummond NF; Conte JA; Rothman SM
    Am J Public Health; 2006 Nov; 96(11):1979-88. PubMed ID: 17018815
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Impact of gene patents and licensing practices on access to genetic testing and carrier screening for Tay-Sachs and Canavan disease.
    Colaianni A; Chandrasekharan S; Cook-Deegan R
    Genet Med; 2010 Apr; 12(4 Suppl):S5-S14. PubMed ID: 20393311
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Preconception risk assessment for thalassaemia, sickle cell disease, cystic fibrosis and Tay-Sachs disease.
    Hussein N; Weng SF; Kai J; Kleijnen J; Qureshi N
    Cochrane Database Syst Rev; 2015 Aug; 2015(8):CD010849. PubMed ID: 26264938
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Cost-effectiveness of a school-based Tay-Sachs and cystic fibrosis genetic carrier screening program.
    Warren E; Anderson R; Proos AL; Burnett LB; Barlow-Stewart K; Hall J
    Genet Med; 2005 Sep; 7(7):484-94. PubMed ID: 16170240
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The frequency of Tay-Sachs disease causing mutations in the Brazilian Jewish population justifies a carrier screening program.
    Rozenberg R; Pereira Lda V
    Sao Paulo Med J; 2001 Jul; 119(4):146-9. PubMed ID: 11500789
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Lower frequency of Gaucher disease carriers among Tay-Sachs disease carriers.
    Peleg L; Frisch A; Goldman B; Karpaty M; Narinsky R; Bronstein S; Frydman M
    Eur J Hum Genet; 1998; 6(2):185-6. PubMed ID: 9781065
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Carrier testing for autosomal-recessive disorders.
    Vallance H; Ford J
    Crit Rev Clin Lab Sci; 2003 Aug; 40(4):473-97. PubMed ID: 14582604
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Nightmare or the dream of a new era in genetics?
    Kolata G
    N Y Times Web; 1993 Dec; ():A1, C3. PubMed ID: 11646996
    [No Abstract]   [Full Text] [Related]  

  • 17. Carrier screening for Gaucher disease: lessons for low-penetrance, treatable diseases.
    Zuckerman S; Lahad A; Shmueli A; Zimran A; Peleg L; Orr-Urtreger A; Levy-Lahad E; Sagi M
    JAMA; 2007 Sep; 298(11):1281-90. PubMed ID: 17878420
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Ethical issues related to BRCA gene testing in orthodox Jewish women.
    Mor P; Oberle K
    Nurs Ethics; 2008 Jul; 15(4):512-22. PubMed ID: 18515440
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Cystic fibrosis heterozygote screening in the Orthodox Community of Ashkenazi Jews: the Dor Yesharim approach and heterozygote frequency.
    Abeliovich D; Quint A; Weinberg N; Verchezon G; Lerer I; Ekstein J; Rubinstein E
    Eur J Hum Genet; 1996; 4(6):338-41. PubMed ID: 9043867
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Prenatal panel screening considerations for non-neuronopathic Gaucher disease in the Ashkenazi-Jewish population.
    Kannai R; Chertok IR
    Isr Med Assoc J; 2006 May; 8(5):347-50. PubMed ID: 16805236
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.